Navigation Links
Study shows PFO closure may be superior to medical therapy in preventing stroke
Date:10/25/2012

HOUSTON (Oct. 25, 2012) Results of a large-scale, randomized clinical trial called RESPECT revealed that patent foramen ovale (PFO) closure may be superior to medical therapy in preventing recurrent stroke, according to a presentation of findings today at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Miami.

"In contrast to a previously reported randomized trial for the treatment of cryptogenic stroke, the RESPECT trial enrolled only patients with documented cryptogenic embolic strokes and excluded patients with other potential causes of stroke and/or TIA. The period of follow-up approached nine years and was not restricted to only events within the initial two years of follow-up," said Richard Smalling, M.D., Ph.D., James D. Wood Distinguished Chair in Cardiovascular Medicine at The University of Texas Health Science Center at Houston (UTHealth), who served on the steering committee and as a principal investigator of the trial.

"As a result, the trial enrolled patients at high-risk for recurrent events and followed them for a long period of time, enabling the detection of relatively infrequent recurrent stroke," said Smalling, who is director of interventional cardiovascular medicine at the Memorial Hermann Heart and Vascular Institute. "The totality of evidence in the RESPECT trial clearly demonstrates the superiority of device closure using the Amplatzer PFO Occluder in patients with the above entry criteria compared to standard medical therapy."

According to the National Institutes of Health, a PFO is a hole between the left and right atria (upper chambers) of the heart that fails to close naturally soon after a baby is born. In about one in four people, the hole never closes. The condition is usually not treated unless there are other heart problems or the person has a stroke caused by a blood clot. PFO has been a suspected cause of cryptogenic stroke, meaning a stroke without any identifiable cause usually occurring in people under the age of 55.

The trial enrolled 980 patients from 69 sites over eight years, yielding 2,300 patient-years of data. Medical group regimens were antiplatelet medications or warfarin. All primary endpoint events were recurrent ischemic strokes. As treated, five of the patients in the closure group had a stroke compared to 16 in the medically treated group.

"These patients with cryptogenic stroke are typically young and in the height of the productive period of their lives. Preventing a recurrent, potentially devastating, stroke by implanting a small device with very little risk is a huge potential benefit," Smalling said.


'/>"/>
Contact: Deborah Mann Lake
deborah.m.lake@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... ... Engineering (ISPE) will host its 2017 Process Validation and Process Validation ... offer comprehensive solutions to process validation lifecycle challenges faced by process validation ...
(Date:7/26/2017)... ... 2017 , ... A global center of excellence specializing in ... of the art center will provide advanced surgical care (heart surgery), management of ... patients longer lives. , North American Veterinary Heart Center, the “Heart Center,” will ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... innovative specialty pharmacies, has released an updated version of the HCV Treatment Path ... for treating chronic hepatitis C virus (HCV) infection. All of the latest HCV ...
(Date:7/25/2017)... ... 25, 2017 , ... Creative Pharmacist and ... the Pharmacist eCare Plan to Computer-Rx pharmacies through the STRAND platform. ... to develop the Pharmacist eCare Plan, a shared document detailing a patient’s current ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Gina Negrette, a ... more than a decade of experience in psychiatry, treating clients in diverse settings, ... eating disorders, psychotic and manic conditions, as well as those who were fighting ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... The Institute for In Vitro Sciences (IIVS), ... of a VITROCELL® inhalation exposure system thanks to a ... device, which is designed to replace animals in inhalation ... to airborne test materials in an environment that mimics ... for testing combustible tobacco products, as well as next ...
(Date:7/10/2017)... , July 10, 2017  The tenth annual ... Boston, MA at the Sheraton Boston ... and unparalleled access to global decision makers and innovative ... 800+ life science leaders during two impactful days. BioPharm ... provides delegates with additional networking opportunities with 4,500+ life ...
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
Breaking Medicine Technology: